AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer